


# Advancing innovative NID1-targeted therapeutics for oncology:

## Preclinical development of antibodies and antibody-drug conjugates

Principal Investigator: Judy Yam


### Discovery platform



### NID1 is upregulated in multiple human cancer types


Upregulation of circulating NID1 in cancer patients suggests NID1 is a potential non-invasive biomarker.

The multiple involvement in various human cancer types suggests NID1 is a promising therapeutic target.




### Identify Nidogen 1 (NID1) as a key driver of cancer progression and metastasis

NID1 is a basement membrane component, secretory free protein and extracellular vesicle cargo.




### Pipelines



### Advantages

- Growing global cancer incidence increases demand for effective therapies
- First-in-class NID1-targeted anti-cancer therapeutic antibodies
- Applicable to a wide spectrum of human cancers expand market reach
- Broad therapeutic potential
- Meet unmet medical needs with innovative targeted treatment options

### Roadmap of NID1 antibody development



### Intellectual property



Granted:

US Patent No. 12,099,061

Pending:

US CIP Patent Application No. 18/461,081

PCT Application No. PCT/CN2024/081342

jyam@hku.hk



HKU Med

LKS Faculty of Medicine  
The University of Hong Kong  
香港大學李嘉誠醫學院



DiagnoUEX Therapeutics  
逸偉生物科技